As such, she designed a novel randomized clinical trial at Stanford, to test the effectiveness of neoadjuvant partial breast irradiation followed by delayed lumpectomy surgery for women with ductal carcinoma in situ (NORDIS: NeOadjuvant Radiation of Ductal Carcinoma In Situ). Dr Wapnir’s efforts focus on extending therapeutic options and advancing the treatment of breast cancer. Nationally, she has been continuously engaged in clinical trials as a member of the NRG Breast Locoregional Subcommittee and NCI-BOLD Task Force. Based on these, she co-chaired the CALOR (Chemotherapy for isolated locoregional recurrence of breast cancer) trial, that has since defined the use of systemic therapies for this patient population. She conducted studies on the impact of breast cancer locoregional recurrences with colleagues from the NSABP (NRG Oncology) Cooperative Oncology Group. Her past bench research centered on elucidating the activity of the sodium iodide symporter in lactation and breast cancer. Wapnir’s work in the field of breast oncology spans clinical and translational research. Vice Provost for Undergraduate Educationĭr.Office of Vice President for Business Affairs and Chief Financial Officer.Office of VP for University Human Resources.Stanford Woods Institute for the Environment.Stanford Institute for Economic Policy Research (SIEPR).Institute for Stem Cell Biology and Regenerative Medicine.Institute for Human-Centered Artificial Intelligence (HAI).Institute for Computational and Mathematical Engineering (ICME).Freeman Spogli Institute for International Studies.Stanford Doerr School of Sustainability.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |